# Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

> **NCT06580054** · PHASE2 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 22 (estimated)

## Conditions studied

- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

## Interventions

- **PROCEDURE:** Computed Tomography
- **OTHER:** Digital Photography
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06580054
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-05
- **Primary completion:** 2028-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06580054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06580054, "Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06580054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*